Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(14):1055-1057; doi:10.1093/jnci/96.14.1055
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Garber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garber, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

NEWS

Trial Results Boost Circulating Tumor Cell Field

Ken Garber

The first 150 words of the full text of this article appear below.

Tumor cells that invade the blood-stream and reach distant organs are the seeds of death. "Patients with cancer... don't die from the primary tumor, they always die from metastases," said Leon Terstappen, M.D., Ph.D., chief scientific officer of Immunicon, a Pennsylvania biotechnology company. Because tumor cells make their way to the site of distant metastases via the bloodstream, "there must be cells there," Terstappen pointed out.

In theory, finding such circulating tumor cells, or CTCs, could identify metastatic disease at its very earliest stage. But the technical hurdles for creating such a clinical test are enormous. "We're looking for really one cell, a weird cell, in a background of maybe 20 million cells," said David Krag, M.D., professor of surgery at the University of Vermont. "Boy, that can be really tough."

But research into circulating tumor cells took a big leap forward in June. In a talk at the American . . . [Full Text of this Article]

A Word of Caution

The Prognosis for Prognosis

Biopsy in Blood?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
V. Muller, N. Stahmann, S. Riethdorf, T. Rau, T. Zabel, A. Goetz, F. Janicke, and K. Pantel
Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity
Clin. Cancer Res., May 15, 2005; 11(10): 3678 - 3685.
[Abstract] [Full Text] [PDF]